uracil has been researched along with Clostridioides difficile Infection in 1 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| " This review therefore examines the evolution of DNA pol IIIC inhibitors from the discovery of 6-(p-hydroxyphenylazo)uracil (HPUra) in the 1960s to the development of current first-in-class N7-substituted guanine drug candidate ACX-362E, now under clinical development for the treatment of Clostridioides difficile infection." | 5.01 | Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections. ( Brown, N; Silverman, MH; Wright, G; Xu, WC; Yu, XY, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, WC | 1 |
| Silverman, MH | 1 |
| Yu, XY | 1 |
| Wright, G | 1 |
| Brown, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment[NCT04247542] | Phase 2 | 32 participants (Actual) | Interventional | 2020-03-06 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uracil and Clostridioides difficile Infection
| Article | Year |
|---|---|
Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections.
Topics: Clostridioides difficile; Clostridium Infections; DNA Polymerase III; Drug Discovery; Humans; Microb | 2019 |